United Therapeutics CEO Martine Rothblatt Sells Shares
CEO Martine Rothblatt sold 9,500 shares of United Therapeutics on June 18, 2026.
Key Points
- Martine Rothblatt, CEO of United Therapeutics, sold 9,500 shares on June 18, 2026, with the stock trading near $539.81.
- United Therapeutics has a market cap of approximately $22.8 billion and a P/E ratio of 19.9, with shares ranging from $272.12 to $609.35 over the past year.
- Institutional activity includes BlackRock increasing its stake by 228,883 shares and Wellington Management reducing its holdings by 177,245 shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Martine Rothblatt, the Chairperson and CEO of United Therapeutics Corporation, sold 9,500 shares of the company on June 18, 2026. This transaction was not part of a pre-planned trading program. Shares of United Therapeutics, trading under the ticker UTHR on the NasdaqGS, were priced around $539.81 on Tuesday.
Insider Buying and Selling at United Therapeutics Corporation
On June 18, 2026, Martine Rothblatt, Chairperson and CEO of United Therapeutics, sold 9,500 shares at an average price of $540.18. This sale was not executed under a Rule 10b5-1 trading plan. Additionally, James Edgemond, CFO and Treasurer, also sold 10,000 shares on the same day at an average price of $540.15, in a planned transaction.
Other Institutional Activity in United Therapeutics
BlackRock, Inc. increased its position in United Therapeutics by 228,883 shares, bringing its total holdings to approximately 5.4 million shares valued at about $3.2 billion. Avoro Capital Advisors LLC slightly boosted its stake by 23,940 shares, ending with 2.63 million shares worth around $1.56 billion. In contrast, Wellington Management Group LLP reduced its holdings by 177,245 shares, leaving it with about 2.26 million shares valued at $1.34 billion. Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both opened new positions, acquiring 2.00 million and 1.96 million shares, respectively.
United Therapeutics Corporation Stock Up 5.6%
Shares of United Therapeutics traded near $539.81 on Tuesday. The company boasts a market capitalization of approximately $22.8 billion and a P/E ratio of 19.9. Its 52-week trading range has seen lows of $272.12 and highs of $609.35. The stock's 50-day moving average is $565.40, while the 200-day moving average stands at $497.47. United Therapeutics has a current ratio of 4.79 and a quick ratio of 4.12, indicating strong liquidity.
$UTHR stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
United Therapeutics reported revenue of around $3.17 billion, though it experienced a slight revenue decline of 1.6%. The company's net margin was 40.6%, and it achieved a return on equity of 20.3%. The next earnings report is expected on July 29, 2026.
Analysts Set New Price Targets
On May 7, 2026, RBC Capital maintained its "buy" rating on United Therapeutics with a price target of $701. Wells Fargo also upgraded the stock to a "buy" with a target of $738. Morgan Stanley maintained a "hold" rating with a target of $519 from April 10, 2026. The consensus among analysts is a "buy" rating, with an average target price of $665.23 based on 13 opinions.
About United Therapeutics
United Therapeutics Corporation is a healthcare company based in Silver Spring, Maryland. It focuses on developing and commercializing products for patients with chronic and life-threatening diseases. The company offers a range of treatments for pulmonary arterial hypertension (PAH) and high-risk neuroblastoma, among other conditions. Founded in 1996, it is led by CEO Dr. Martine Rothblatt and employs around 1,400 people.
Bottom Line
Martine Rothblatt's recent sale of shares provides insight into insider activity at United Therapeutics. Investors often track such transactions for potential signals, though they aren't definitive indicators of future performance. United Therapeutics continues to be a significant player in the healthcare sector, with a solid market presence and a range of innovative products. As always, it's important to remember that insider transactions are disclosed after the fact and may not reflect current positions.
Get United Therapeutics Corporation alerts
New 13F filings, insider trades, and analyst moves on $UTHR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.